Regenxbio (RGNX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov6

Regenxbio released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 29.73 M (forecast USD 24.41 M), actual EPS USD -1.1983 (forecast USD -1.34)

14:30

Regenxbio released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 140.1 M and actual EPS of USD -2.4581

14:30

Oct30

Regenxbio to release FY2025 Q3 earnings on November 6, pre-market EST, with forecast revenue of USD 24.41 M and EPS of USD -1.34

00:08

Oct6

REGENXBIO Completes Key Trial Recruitment for Wet AMD Treatment Drug

11:13

Sep5

Regenxbio Inc. Submits RGX-121 Hunting Syndrome Gene Therapy Trial Results to FDA

11:05

Aug7

Regenxbio released FY2025 Q2 earnings on August 7 Pre-Market EST, actual revenue USD 21.36 M (forecast USD 40.87 M), actual EPS USD -1.38 (forecast USD -0.8964)

13:30